Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 502

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 502
---
 398,939 NLS Common Shares at an exercise price of $1.80 per share. The net proceeds and related instruments have been reflected in the pro forma financial statements accordingly; (D)Adjustment to remove $104,963 of interest expenses related to loans converted at closing as noted above as if Merger took place January1, 2024; 273 (E)Adjustment to record additional non -recurringNLS transaction costs of approximately $550,000 for legal, audit and other professional service provider expenses and director and officer tail insurance that were not incurred or accrued as part of the transaction costs recorded as of December31, 2024 of $743,838. For the transactions costs incurred and recorded subsequent to December31, 2024, $250,000 has been paid in cash and $300,000 has been accrued for purposes of payment subsequent to the closing; (E)Adjustment to record additional non -recurringKadimastem transaction costs of approximately $300,000 for legal, audit and other professional service provider expenses that were not incurred or accrued as part of the transaction costs recorded as of December31, 2024 of $268,729. For the transactions costs incurred and recorded subsequent to December31, 2024, $100,000 has been paid in cash and $200,000 has been accrued for purposes of payment subsequent to the closing; (F)Adjustment for $18,229 to record conversion of 551,532 of the Company’s PPCs, par value CHF 0.03 per certificate, pursuant to the securities purchase agreement entered into a with an accredited investor on October9, 2024 to satisfy $4.0million of our debt (“October 2024 Debt SPA”) into 754,384 NLS Common Shares issued which included anti -dilutionshares as outlined per the agreement and resulted in adjustment of $24,933; (G)Adjustment of $11,898 to record 360,000 PPCs, par value CHF 0.03 per certificate, convertible into NLS Common Shares issued in addition to anti -dilutionNLS Common Shares referenced above in satisfaction of the anti -dilutionrights of the Selling Shareholder under the October Debt SPA; (H)Adjustment for the twelve months ended December31, 2024 of $61,438 to accelerate share -basedcompensation expense for NLS options based on IFRS accounting requirements at closing of Merger;